Clinical Trial Update: Protective Effects of Oral L-Arginine CI-AKI [Phase 4]

View source ↗

Summary

Phase 4 clinical trial update evaluating whether oral L-Arginine can protect against contrast-induced acute kidney injury. Current status is unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Contrast-induced Acute Kidney Injury

Drugs mentioned

• L-Arginine (L-Arginine)

Snippet

Sponsor: Phramongkutklao College of Medicine and Hospital | Conditions: Contrast Induced AKI | Phase 4 | Status: UNKNOWN